BCL2 and Miyoshi myopathy: Furthermore, targeting MM glutamine metabolism has been confirmed to enhance the binding of the BIM gene to BCL-2, thereby increasing the sensitivity of MM cells to Venetoclax, providing an effective treatment strategy for relapsed refractory MM [56].